B
6.95
0.19 (2.81%)
| Previous Close | 6.76 |
| Open | 6.78 |
| Volume | 3,715,549 |
| Avg. Volume (3M) | 4,168,686 |
| Market Cap | 1,723,871,360 |
| Price / Earnings (Forward) | 454.55 |
| Price / Sales | 3.10 |
| Price / Book | 56.59 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Profit Margin | -10.62% |
| Operating Margin (TTM) | 14.59% |
| Diluted EPS (TTM) | -0.260 |
| Quarterly Revenue Growth (YOY) | 56.90% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -25.85 M |
| Levered Free Cash Flow (TTM) | 42.90 M |
| Return on Assets (TTM) | 4.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | BioCryst Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.80 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 1.20% |
| % Held by Institutions | 87.44% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (HC Wainwright & Co., 360.43%) | Buy |
| Median | 22.50 (223.74%) | |
| Low | 13.00 (RBC Capital, 87.05%) | Buy |
| Average | 22.50 (223.74%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 30 Jan 2026 | 13.00 (87.05%) | Buy | 6.58 |
| HC Wainwright & Co. | 15 Dec 2025 | 32.00 (360.43%) | Buy | 7.59 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRANK STEVEN | 8.75 | - | 1,285 | 11,244 |
| MCKEE AMY E | 8.75 | - | 642 | 5,618 |
| MILANO VINCENT | 8.75 | - | 848 | 7,420 |
| MILNE JILL C. | 8.75 | - | 528 | 4,620 |
| STONEHOUSE JON P | 8.75 | 8.63 | -305,574 | -2,637,053 |
| Aggregate Net Quantity | -302,271 | |||
| Aggregate Net Value ($) | -2,608,152 | |||
| Aggregate Avg. Buy ($) | 8.75 | |||
| Aggregate Avg. Sell ($) | 8.63 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STONEHOUSE JON P | Director | 02 Mar 2026 | Automatic sell (-) | 305,995 | 8.63 | 2,640,737 |
| STONEHOUSE JON P | Director | 02 Mar 2026 | Option execute | 305,995 | - | - |
| MCKEE AMY E | Director | 27 Feb 2026 | Acquired (+) | 642 | 8.75 | 5,618 |
| FRANK STEVEN | Director | 27 Feb 2026 | Acquired (+) | 1,285 | 8.75 | 11,244 |
| MILANO VINCENT | Director | 27 Feb 2026 | Acquired (+) | 848 | 8.75 | 7,420 |
| STONEHOUSE JON P | Director | 27 Feb 2026 | Acquired (+) | 421 | 8.75 | 3,684 |
| MILNE JILL C. | Director | 27 Feb 2026 | Acquired (+) | 528 | 8.75 | 4,620 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 |
| 05 Feb 2026 | Announcement | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Jan 2026 | Announcement | BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema |
| 12 Jan 2026 | Announcement | BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range |
| 06 Jan 2026 | Announcement | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Announcement | BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 12 Dec 2025 | Announcement | BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |